Chun Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chun Wang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Anni Chen
Comprehensive Cancer Centre Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine Nanjing University of Chinese Medicine Nanjing 210008 China
1 shared publicationAoxing Chen
The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital Affiliated Hospital of Medical School Nanjing University Nanjing 210008 China
1 shared publicationBaorui Liu
The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital Affiliated Hospital of Medical School Nanjing University Nanjing 210008 China
1 shared publication- Bin Xue
Nanjing University
1 shared publication Gaojian Tao
Department of Pain Management Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing 210008 China
1 shared publicationJie Gu
Collaborative Innovation Centre of Advanced Microstructures National Laboratory of Solid State Microstructure Key Laboratory of Intelligent Optical Sensing and Manipulation, Ministry of Education, Department of Physics Nanjing University Nanjing 210008 China
1 shared publication
Latest Publications
- RetractedOpen Access
- 31 August 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (26) , e2300877
RETRACTED: Bivalent Gadolinium Ions Forming Injectable Hydrogels for Simultaneous In Situ Vaccination Therapy and Imaging of Soft Tissue Sarcoma
Doxorubicin (DOX) is the classic soft tissue sarcomas (STS) first‐line treatment drug, while dose‐dependent myelosuppression and cardiotoxicity limit its application in clinic. This research intends to apply DOX, which is also an inducer of immunogenic cell death as a part for “in situ vaccination” and conjointly uses PD‐1 inhibitors to enhance antitumor efficacy. In order to achieve the sustained vaccination effect and real‐time monitoring of distribution in vivo, the in situ forming and injectable hydrogel platform with the function of visualization is established for local delivery. The hydrogel platform is synthesized by hyaluronic acid‐dopamine coordinated with gadolinium ions (Gd 2+ ). Gd 2+ provides the ability of magnetic resonance imaging, meanwhile further cross‐linking the hydrogel network. Experiments show excellent ability of sustained release and imaging tracking for the hydrogel platform. In mouse STS models, the “in situ vaccination” hydrogels show the best effect of inhibiting tumor growth. Further analysis of tumor tissues show that “in situ vaccination” group can increase T cell infiltration, promote M1‐type macrophage polarization and block elevated PD‐1/PD‐L1 pathway caused by DOX. These results are expected to prove the potential for synthesized hydrogels to achieve a universal platform for “in situ vaccination” strategies on STS treatments.
- 31 August 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (26) , e2300877
RetractedOpen AccessRETRACTED: Bivalent Gadolinium Ions Forming Injectable Hydrogels for Simultaneous In Situ Vaccination Therapy and Imaging of Soft Tissue Sarcoma
Doxorubicin (DOX) is the classic soft tissue sarcomas (STS) first‐line treatment drug, while dose‐dependent myelosuppression and cardiotoxicity limit its application in clinic. This research intends to apply DOX, which is also an inducer of immunogenic cell death as a part for “in situ vaccination” and conjointly uses PD‐1 inhibitors to enhance antitumor efficacy. In order to achieve the sustained vaccination effect and real‐time monitoring of distribution in vivo, the in situ forming and injectable hydrogel platform with the function of visualization is established for local delivery. The hydrogel platform is synthesized by hyaluronic acid‐dopamine coordinated with gadolinium ions (Gd 2+ ). Gd 2+ provides the ability of magnetic resonance imaging, meanwhile further cross‐linking the hydrogel network. Experiments show excellent ability of sustained release and imaging tracking for the hydrogel platform. In mouse STS models, the “in situ vaccination” hydrogels show the best effect of inhibiting tumor growth. Further analysis of tumor tissues show that “in situ vaccination” group can increase T cell infiltration, promote M1‐type macrophage polarization and block elevated PD‐1/PD‐L1 pathway caused by DOX. These results are expected to prove the potential for synthesized hydrogels to achieve a universal platform for “in situ vaccination” strategies on STS treatments.